ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion

Morgen haben doch die Börsen zu

nein usa offen bis 19 MEZ

Oder langsam aussteigen weil sehr stark überbewertet und heiß gelaufen….

im gegenteil.nach 25% korrektur wieder fair bewertet nach den super aussichten.

STUDY: OZEMPIC LINKED TO VISION CHANGES AND EYE DISEASE RISKS Ozempic, a diabetes and weight-loss drug, may cause blurred vision, worsen diabetic retinopathy, and increase eye disease risks, as revealed by retina specialist Raj Maturi, MD. Experts say blurred vision is usually temporary, subsiding after 3-4 months. However, patients with diabetes should monitor for worsening retinopathy. A possible link to a rare blinding disease, NAION, is under study, but no definitive causal link has been established. Patients should consult their doctors before starting semaglutide (Ozempic) and get regular eye exams to track potential side effects. Source: American Academy of Ophthalmology https://x.com/MarioNawfal/status/1872341575990194550?t=P4SNWv__d3sqg_n2tExK5Q&s=19

nein im gegenteil.börse steigt weil die grossen player nicht mehr shorten.und die kleinen kaufen.

vor Weihnachten und bis Silvester rechne ich sowieso wie jedes Jahr mit Gewinnmitnahmen.

So mal wieder auf die 800 steigen 😁

was für ein hin und her am FR- schätze wir kommen bald an das obere Ende ( Vormittgaskurs) zurück

doch plus 3% gegenüber usa schluss

Aktie reagiert nicht auf die Zulassung

🤩

Eli Lilly’s $LLY Zepbound approval for sleep apnea in obese patients is transformative. Untreated sleep apnea costs the U.S. $149.6B yearly—$87B in lost productivity, $26B in vehicle accidents, $7B in workplace incidents. Zepbound could help $LLY The Food and Drug Administration approved Eli Lilly’s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted during sleep due to narrowed or blocked airways. The agency’s decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

Es müsste Montag steigen oder ?

https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription#:~:text=INDIANAPOLIS%20%2C%20Dec.%2020%2C%202024,apnea%20(OSA)%20and%20obesity.